메뉴 건너뛰기




Volumn 108, Issue 6, 2013, Pages 1238-1244

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

EID: 84876420292     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.83     Document Type: Article
Times cited : (46)

References (32)
  • 2
  • 10
    • 34548398070 scopus 로고    scopus 로고
    • Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
    • Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33: 565-577.
    • (2007) Cancer Treat Rev , vol.33 , pp. 565-577
    • Gossage, L.1    Madhusudan, S.2
  • 14
    • 36849088076 scopus 로고    scopus 로고
    • Molecular prognostic markers in locally advanced colon cancer
    • Lurje G, Zhang W, Lenz HJ (2007) Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer 6: 683-690.
    • (2007) Clin Colorectal Cancer , vol.6 , pp. 683-690
    • Lurje, G.1    Zhang, W.2    Lenz, H.J.3
  • 15
    • 40949130371 scopus 로고    scopus 로고
    • Platinum resistance: The role of DNA repair pathways
    • Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14: 1291-1295.
    • (2008) Clin Cancer Res , vol.14 , pp. 1291-1295
    • Martin, L.P.1    Hamilton, T.C.2    Schilder, R.J.3
  • 16
    • 84866769442 scopus 로고    scopus 로고
    • Oxaliplatin as part of adjuvant therapy for colon cancer: More complicated than once thought
    • Mayer RJ (2012) Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol 30: 3325-3327.
    • (2012) J Clin Oncol , vol.30 , pp. 3325-3327
    • Mayer, R.J.1
  • 18
    • 33846404174 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance and toxicity associated with platinating agents
    • Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
    • (2007) Cancer Treat Rev , vol.33 , pp. 9-23
    • Rabik, C.A.1    Dolan, M.E.2
  • 21
    • 0032866230 scopus 로고    scopus 로고
    • Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin
    • Scheeff ED, Briggs JM, Howell SB (1999) Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 56: 633-643.
    • (1999) Mol Pharmacol , vol.56 , pp. 633-643
    • Scheeff, E.D.1    Briggs, J.M.2    Howell, S.B.3
  • 22
    • 0036849436 scopus 로고    scopus 로고
    • Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin
    • Sharp SY, O'Neill CF, Rogers P, Boxall FE, Kelland LR (2002) Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur J Cancer 38: 2309-2315.
    • (2002) Eur J Cancer , vol.38 , pp. 2309-2315
    • Sharp, S.Y.1    O'Neill, C.F.2    Rogers, P.3    Boxall, F.E.4    Kelland, L.R.5
  • 25
    • 3843130823 scopus 로고    scopus 로고
    • A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
    • Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344-354.
    • (2004) Br J Cancer , vol.91 , pp. 344-354
    • Stoehlmacher, J.1    Park, D.J.2    Zhang, W.3    Yang, D.4    Groshen, S.5    Zahedy, S.6    Lenz, H.J.7
  • 27
    • 0033600558 scopus 로고    scopus 로고
    • Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts
    • Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, Turchi JJ, Chaney SG (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry-Us 38: 11026-11039.
    • (1999) Biochemistry-Us , vol.38 , pp. 11026-11039
    • Vaisman, A.1    Lim, S.E.2    Patrick, S.M.3    Copeland, W.C.4    Hinkle, D.C.5    Turchi, J.J.6    Chaney, S.G.7
  • 29
    • 24344479165 scopus 로고    scopus 로고
    • ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
    • Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F (2005) ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212-6217.
    • (2005) Clin Cancer Res , vol.11 , pp. 6212-6217
    • Viguier, J.1    Boige, V.2    Miquel, C.3    Pocard, M.4    Giraudeau, B.5    Sabourin, J.C.6    Ducreux, M.7    Sarasin, A.8    Praz, F.9
  • 30
    • 0035964610 scopus 로고    scopus 로고
    • A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer
    • Watanabe Y, Koi M, Hemmi H, Hoshai H, Noda K (2001) A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 85: 1064-1069.
    • (2001) Br J Cancer , vol.85 , pp. 1064-1069
    • Watanabe, Y.1    Koi, M.2    Hemmi, H.3    Hoshai, H.4    Noda, K.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.